Hepatoma/merbarone. A Southwest Oncology Group study.
Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.
Poplin
E A
EA
Wayne State University Medical Center, Detroit, MI, USA.
Tangen
C M
CM
Harvey
W H
WH
Macdonald
J S
JS
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013858:Thiobarbiturates / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013858:Thiobarbiturates; C045459:merbarone